Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens Senator Bernie Sanders called for HHS Secretary RFK Jr.'s resignation over his anti-vaccine policies, ousting of CDC Director Susan Monarez.
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health' Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.
Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.
CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.
GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’ GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.
After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.
GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.
GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision.
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.
GSK Stock Gains As Flu Vaccine Rollout Begins And US Recovers From Most Severe Season In 15 Years Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré syndrome.
Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.
CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panel The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations.
